DGIdb - PHENYTOIN Drug Record

PHENYTOIN chembl:CHEMBL16 Approved

Alternate Names:

DILABID
PHENYTEK
DILANTIN-125
HYDANTOL
NSC-8722
DIPHENYLHYDANTOIN
PHENYTEX
PHENYTOIN
SM-88 COMPONENT PHENYTOIN
PHENTYTOIN
DILANTIN-30
DILANTIN
PHENYTEX®
5,5-DIPHENYL-IMIDAZOLIDINE-2,4-DIONE
PHENYTOIN SODIUM
5,5-DIPHENYLTETRAHYDRO-1H-2,4-IMIDAZOLEDIONE
5,5-DIPHENYLIMIDAZOLIDINE-2,4-DIONE
DILANTIN®
FENITOINA
PHENYTOINE
EPANUTIN®
PHENYTOINUM
pubchem.compound:1775
drugbank:00252
chemidplus:57-41-0
rxcui:8183
chembl:CHEMBL16

Drug Info:

Drug Categories	hydantoins
Drug Categories	cytochrome p-450 cyp2c8 inducers (strong)
Drug Categories	cytochrome p-450 cyp2c19 inducers (strong)
FDA Approval	Approved before 1982
Drug Class	small molecule
Drug Indications	Anticonvulsants
Drug Class	anticonvulsants
Year of Approval	approved before 1982
Drug Categories	agents causing muscle toxicity
Drug Categories	anti-epileptic agent
Drug Categories	comt substrates
Drug Categories	cytochrome p-450 cyp1a2 inducers (strength unknown)
Drug Categories	cytochrome p-450 cyp2a6 substrates
Drug Categories	cytochrome p-450 cyp2b6 inducers (strength unknown)
Drug Categories	cytochrome p-450 cyp2b6 substrates
Drug Categories	cytochrome p-450 cyp2c18 substrates
Drug Categories	cytochrome p-450 cyp2c18 substrates with a narrow therapeutic index
Drug Categories	cytochrome p-450 cyp2c19 inducers (moderate)
Drug Categories	cytochrome p-450 cyp2c19 substrates with a narrow therapeutic index
Drug Categories	cytochrome p-450 cyp2c8 substrates with a narrow therapeutic index
Drug Categories	cytochrome p-450 cyp2c9 inducers (strength unknown)
Drug Categories	cytochrome p-450 cyp2c9 inhibitors (strength unknown)
Drug Categories	cytochrome p-450 cyp2c9 substrates with a narrow therapeutic index
Drug Categories	cytochrome p-450 cyp2d6 substrates
Drug Categories	cytochrome p-450 cyp2e1 substrates
Drug Categories	cytochrome p-450 cyp3a inducers (strong)
Drug Categories	cytochrome p-450 cyp3a substrates
Drug Categories	cytochrome p-450 cyp3a4 inducers
Drug Categories	cytochrome p-450 cyp3a5 inducers
Drug Categories	cytochrome p-450 cyp3a5 inducers (strength unknown)
Drug Categories	cytochrome p-450 cyp3a5 substrates
Drug Categories	cytochrome p-450 cyp3a7 inducers
Drug Categories	cytochrome p-450 cyp3a7 inducers (weak)
Drug Categories	cytochrome p-450 cyp3a7 substrates
Drug Categories	cytochrome p-450 enzyme inhibitors
Drug Categories	cytochrome p-450 substrates
Drug Categories	decreased central nervous system disorganized electrical activity
Drug Categories	enzyme inducing antiepileptic drugs
Drug Categories	narrow therapeutic index drugs
Drug Categories	p-glycoprotein substrates
Drug Categories	p-glycoprotein substrates with narrow therapeutic index
Drug Categories	phenytoin and prodrugs
Drug Categories	thyroxine-binding globulin substrates
Drug Categories	ugt1a1 inducers
Drug Categories	ugt1a1 substrates
Drug Categories	ugt1a4 substrates
Drug Categories	ugt1a6 inhibitors
Drug Categories	ugt1a6 substrate
Drug Categories	ugt1a9 inhibitors
Drug Categories	ugt1a9 substrates

(7 More Sources)

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
Musselman et al., Preliminary evidence of phenytoin-induced alterations in embryonic gene expression in a mouse model., Reprod. Toxicol.
Tate et al., 2006, A common polymorphism in the SCN1A gene associates with phenytoin serum levels at maintenance dose., Pharmacogenet. Genomics
Tate et al., 2005, Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin., Proc. Natl. Acad. Sci. U.S.A.
Mantegazza et al., 2010, Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders., Lancet Neurol
Ericsson et al., Thyroglobulin and thyroid hormones in patients on long-term treatment with phenytoin, carbamazepine, and valproic acid., Epilepsia
Gryn SE et al., 2014, Profound reduction in the tamoxifen active metabolite endoxifen in a patient on phenytoin for epilepsy compared with a CYP2D6 genotype matched cohort., Pharmacogenet Genomics
Mazaleuskaya LL et al., 2015, PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses., Pharmacogenet Genomics
Fleckman et al., 1981, Effect of trifluoperazine, D600, and phenytoin on depolarization- and thyrotropin-releasing hormone-induced thyrotropin release from rat pituitary tissue., Endocrinology
Azzato EM et al., 2010, Maternal EPHX1 polymorphisms and risk of phenytoin-induced congenital malformations., Pharmacogenet Genomics
Haerian BS et al., 2013, SCN1A, SCN2A and SCN3A gene polymorphisms and responsiveness to antiepileptic drugs: a multicenter cohort study and meta-analysis., Pharmacogenomics
Kwan P et al., 2008, Multidrug resistance in epilepsy and polymorphisms in the voltage-gated sodium channel genes SCN1A, SCN2A, and SCN3A: correlation among phenotype, genotype, and mRNA expression., Pharmacogenet Genomics
Ma CL et al., 2014, Association of SCN1A, SCN2A and ABCC2 gene polymorphisms with the response to antiepileptic drugs in Chinese Han patients with epilepsy., Pharmacogenomics
Ohnishi et al., 1997, Direct inhibitions of the activities of steroidogenic cytochrome P-450 mono-oxygenase systems by anticonvulsants., J. Steroid Biochem. Mol. Biol.
Schwahn B et al., 2001, Polymorphisms in the methylenetetrahydrofolate reductase gene: clinical consequences., Am J Pharmacogenomics
Dean et al., 1999, Fetal anticonvulsant syndrome and mutation in the maternal MTHFR gene., Clin. Genet.
Yang M et al., 2012, Therapeutic potential for phenytoin: targeting Na(v)1.5 sodium channels to reduce migration and invasion in metastatic breast cancer., Breast Cancer Res Treat
Mitiushin et al., 1978, [Several types of mitochondrial ultrastructure in animal cell mitochondria and their relationship to energy production]., Tsitologiia
Swadron et al., 2004, A comparison of phenytoin-loading techniques in the emergency department., Acad Emerg Med
Wong et al., 2005, The effects of phenytoin and its metabolite 5-(4-hydroxyphenyl)-5-phenylhydantoin on cellular glucose transport., Life Sci.
Usui et al., 2003, Induction of CYP3As in HepG2 cells by several drugs. Association between induction of CYP3A4 and expression of glucocorticoid receptor., Biol. Pharm. Bull.
Pearce RE et al., 2002, Pathways of carbamazepine bioactivation in vitro I. Characterization of human cytochromes P450 responsible for the formation of 2- and 3-hydroxylated metabolites., Drug Metab Dispos
Di YM et al., 2009, Structure, function, regulation and polymorphism of human cytochrome P450 2A6., Curr Drug Metab
Restrepo JG et al., 2009, Polymorphic drug metabolism in anaesthesia., Curr Drug Metab
Komatsu T et al., 2000, Formation of a dihydroxy metabolite of phenytoin in human liver microsomes/cytosol: roles of cytochromes P450 2C9, 2C19, and 3A4., Drug Metab Dispos
Kimber-Trojnar Z et al., 2003, Perspectives of losigamone in epilepsy treatment., Pol J Pharmacol
Torchin CD et al., 1996, Stereoselective metabolism of a new anticonvulsant drug candidate, losigamone, by human liver microsomes., Drug Metab Dispos
Yang B et al., 2008, Lack of aquaporin-4 water transport inhibition by antiepileptics and arylsulfonamides., Bioorg Med Chem
Talwar P et al., 2017, Genetic contribution of CYP1A1 variant on treatment outcome in epilepsy patients: a functional and interethnic perspective., Pharmacogenomics J
Grover S et al., 2010, Genetic polymorphisms in sex hormone metabolizing genes and drug response in women with epilepsy., Pharmacogenomics
Zanger UM et al., 2007, Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance., Pharmacogenomics
Kobayashi K et al., 2004, Key structural features of ligands for activation of human pregnane X receptor., Drug Metab Dispos
Faucette et al., 2004, Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers., Drug Metab. Dispos.
Turan et al., 2004, Do vascular endothelial growth factor and basic fibroblast growth factor promote phenytoin's wound healing effect in rat? An immunohistochemical and histopathologic study., Dermatol Surg
Lucas PT et al., 2005, An epilepsy mutation in the beta1 subunit of the voltage-gated sodium channel results in reduced channel sensitivity to phenytoin., Epilepsy Res
Keppel Hesselink JM, 2017, Phenytoin: a step by step insight into its multiple mechanisms of action-80 years of mechanistic studies in neuropharmacology., J Neurol
Tutor-Crespo et al., [A study of some indirect biochemical markers in the evaluation of enzymatic induction caused by antiepileptic drugs]., Rev Neurol
Calandre et al., The effect of chronic phenytoin treatment on serum lipid profile in adult epileptic patients., Epilepsia

PHENYTOIN SCN1B

Interaction Score: 1.35

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15922564

Sources:
DrugBank
PHENYTOIN CFHR4

Interaction Score: 1.35

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
PHENYTOIN TRH

Interaction Score: 0.68

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
6262046

Sources:
NCI
PHENYTOIN UGT2B15

Interaction Score: 0.45

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26049587

Sources:
PharmGKB
PHENYTOIN EPHX1

Interaction Score: 0.39

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19952982

Sources:
PharmGKB
PHENYTOIN AQP4

Interaction Score: 0.34

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18572411

Sources:
DTC
PHENYTOIN CYP2A6

Interaction Score: 0.34

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12386121 19702528 19442086 11038165 14704462 8886611

Sources:
PharmGKB
PHENYTOIN POU5F1

Interaction Score: 0.34

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
PHENYTOIN GGT1

Interaction Score: 0.21

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12402220 1346382

Sources:
NCI
PHENYTOIN SLC2A1

Interaction Score: 0.21

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15698863

Sources:
NCI
PHENYTOIN MTHFR

Interaction Score: 0.21

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12083967 10563481

Sources:
NCI PharmGKB
PHENYTOIN UGT1A6

Interaction Score: 0.21

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26049587

Sources:
PharmGKB
PHENYTOIN SCN2A

Interaction Score: 0.17

Interaction Types & Directionality:

blocker (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Sodium channel alpha subunit blocker

Specific Action of the Ligand Pore blocker

PMIDs:
23859570 18784617 15805193 25155934

Sources:
PharmGKB DrugBank GuideToPharmacology ChemblInteractions
PHENYTOIN NTF3

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
7841657

Sources:
NCI
PHENYTOIN CYP1A1

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26951882 21121773

Sources:
PharmGKB
PHENYTOIN TG

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
3935423

Sources:
NCI
PHENYTOIN SCN1A

Interaction Score: 0.14

Interaction Types & Directionality:

blocker (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

Mechanism of Interaction Sodium channel alpha subunit blocker

PMIDs:
17001291 15805193 20298965

Sources:
TEND PharmGKB TdgClinicalTrial DrugBank ChemblInteractions
PHENYTOIN UGT1A9

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26049587

Sources:
PharmGKB
PHENYTOIN SCN5A

Interaction Score: 0.1

Interaction Types & Directionality:

blocker (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

Mechanism of Interaction Sodium channel alpha subunit blocker

PMIDs:
22678159 150666 15001403

Sources:
TEND TdgClinicalTrial DrugBank ChemblInteractions
PHENYTOIN SCN3A

Interaction Score: 0.09

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Sodium channel alpha subunit blocker

PMIDs:
15922564 15805193

Sources:
DrugBank ChemblInteractions
PHENYTOIN NAT2

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
PHENYTOIN SCN8A

Interaction Score: 0.07

Interaction Types & Directionality:

blocker (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

PMIDs:
15805193

Sources:
DrugBank ChemblInteractions
PHENYTOIN CYP19A1

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9182861

Sources:
NCI
PHENYTOIN VEGFA

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15458527

Sources:
NCI
PHENYTOIN HLA-B

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
FDA
PHENYTOIN CYP2B6

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17638512

Sources:
PharmGKB
PHENYTOIN CACNA1C

Interaction Score: 0.05

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
28349209

Sources:
DrugBank
PHENYTOIN NR1I2

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15039302 14977870

Sources:
PharmGKB DrugBank
PHENYTOIN GABRA1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28349209

Sources:
PharmGKB DrugBank
PHENYTOIN CYP3A5

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12673034

Sources:
NCI
PHENYTOIN SCN7A

Interaction Score: 0.02

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Sodium channel alpha subunit blocker

PMIDs:
None found

Sources:
ChemblInteractions
PHENYTOIN SCN11A

Interaction Score: 0.02

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
PHENYTOIN SCN4A

Interaction Score: 0.02

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
PHENYTOIN SCN9A

Interaction Score: 0.02

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
PHENYTOIN SCN10A

Interaction Score: 0.02

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
PHENYTOIN CYP2C9

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC FDA
PHENYTOIN CYP2D6

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300 24915025

Sources:
DTC PharmGKB
PHENYTOIN CYP2C19

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC FDA
PHENYTOIN KCNH2

Interaction Score: 0.01

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
22678159

Sources:
DrugBank
PHENYTOIN CYP1A2

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
PHENYTOIN CYP3A4

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
PHENYTOIN NFE2L2

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

DrugBank: DB00252

Version: 5.1.7

Alternate Names:

PHENYTOIN DrugBank Drug Name

57-41-0 CAS Number

Apo-phenytoin Sodium Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Groups vet_approved

Publications:

Lucas PT et al., 2005, An epilepsy mutation in the beta1 subunit of the voltage-gated sodium channel results in reduced channel sensitivity to phenytoin., Epilepsy Res

Kobayashi K et al., 2004, Key structural features of ligands for activation of human pregnane X receptor., Drug Metab Dispos

Faucette et al., 2004, Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers., Drug Metab. Dispos.

TEND: PHENYTOIN
- Version: 01-August-2011
Alternate Names:

PHENYTOIN Primary Drug Name

Drug Info:

Year of Approval approved before 1982

Drug Class anticonvulsants

Publications:
TdgClinicalTrial: PHENYTOIN
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications Anticonvulsants

Drug Class small molecule

FDA Approval Approved before 1982

Publications:

NCI: PHENYTOIN

Version: 14-September-2017

Alternate Names:

C741 NCI drug code

Drug Info:

Publications:

Ericsson et al., Thyroglobulin and thyroid hormones in patients on long-term treatment with phenytoin, carbamazepine, and valproic acid., Epilepsia

Fleckman et al., 1981, Effect of trifluoperazine, D600, and phenytoin on depolarization- and thyrotropin-releasing hormone-induced thyrotropin release from rat pituitary tissue., Endocrinology

Turan et al., 2004, Do vascular endothelial growth factor and basic fibroblast growth factor promote phenytoin's wound healing effect in rat? An immunohistochemical and histopathologic study., Dermatol Surg

DTC: PHENYTOIN

Version: 02-September-2020

Alternate Names:

CHEMBL16 ChEMBL Drug ID

Drug Info:

Publications:

Yang B et al., 2008, Lack of aquaporin-4 water transport inhibition by antiepileptics and arylsulfonamides., Bioorg Med Chem

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

PharmGKB: phenytoin

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Tate et al., 2006, A common polymorphism in the SCN1A gene associates with phenytoin serum levels at maintenance dose., Pharmacogenet. Genomics

Talwar P et al., 2017, Genetic contribution of CYP1A1 variant on treatment outcome in epilepsy patients: a functional and interethnic perspective., Pharmacogenomics J

Grover S et al., 2010, Genetic polymorphisms in sex hormone metabolizing genes and drug response in women with epilepsy., Pharmacogenomics

TTD: Phenytoin
- Version: 2020.06.01
Alternate Names:

D0E4DW TTD Drug ID

Drug Info:

Publications:
GuideToPharmacology: 53801032
- Version: 29-September-2020
Alternate Names:

PHENYTOIN GuideToPharmacology Ligand Name

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL16
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
FDA: Phenytoin
- Version: 04-September-2020
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL16
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

Direct Interaction	yes
Mechanism of Interaction	Sodium channel alpha subunit blocker
Specific Action of the Ligand	Pore blocker

Trial Name	-
Novel drug target	Established target
Mechanism of Interaction	Sodium channel alpha subunit blocker

PHENYTOIN	DrugBank Drug Name
57-41-0	CAS Number
Apo-phenytoin Sodium	Drug Brand

Drug Type	small molecule
Drug Groups	approved
Drug Groups	vet_approved

blocker (inhibitory)
inhibitor (inhibitory)

blocker (inhibitory)
inhibitor (inhibitory)

blocker (inhibitory)
inhibitor (inhibitory)

PHENYTOIN Drug Record

PHENYTOIN chembl:CHEMBL16 Approved

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15922564

Sources: DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 6262046

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26049587

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 19952982

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18572411

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12386121 19702528 19442086 11038165 14704462 8886611

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12402220 1346382

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15698863

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12083967 10563481

Sources: NCI PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26049587

Sources: PharmGKB

Interaction Types & Directionality: blocker (inhibitory) inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction Sodium channel alpha subunit blocker Specific Action of the Ligand Pore blocker

PMIDs: 23859570 18784617 15805193 25155934

Sources: PharmGKB DrugBank GuideToPharmacology ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 7841657

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26951882 21121773

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 3935423

Sources: NCI

Interaction Types & Directionality: blocker (inhibitory) inhibitor (inhibitory)

Interaction Info: Trial Name - Novel drug target Established target Mechanism of Interaction Sodium channel alpha subunit blocker

PMIDs: 17001291 15805193 20298965

Sources: TEND PharmGKB TdgClinicalTrial DrugBank ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26049587

Sources: PharmGKB

Interaction Types & Directionality: blocker (inhibitory) inhibitor (inhibitory)

Interaction Info: Trial Name - Novel drug target Established target Mechanism of Interaction Sodium channel alpha subunit blocker

PMIDs: 22678159 150666 15001403

Interaction Types & Directionality:

n/a

PMIDs:
15922564

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
6262046

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
26049587

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
19952982

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
18572411

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
12386121 19702528 19442086 11038165 14704462 8886611

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
12402220 1346382

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
15698863

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
12083967 10563481

Sources:
NCI PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
26049587

Sources:
PharmGKB

Interaction Types & Directionality:

blocker (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Sodium channel alpha subunit blocker

Specific Action of the Ligand Pore blocker

PMIDs:
23859570 18784617 15805193 25155934

Sources:
PharmGKB DrugBank GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
7841657

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
26951882 21121773

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
3935423

Sources:
NCI

Interaction Types & Directionality:

blocker (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

Mechanism of Interaction Sodium channel alpha subunit blocker

PMIDs:
17001291 15805193 20298965

Sources:
TEND PharmGKB TdgClinicalTrial DrugBank ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
26049587

Sources:
PharmGKB

Interaction Types & Directionality:

blocker (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

Mechanism of Interaction Sodium channel alpha subunit blocker

PMIDs:
22678159 150666 15001403

Sources:
TEND TdgClinicalTrial DrugBank ChemblInteractions

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Sodium channel alpha subunit blocker

PMIDs:
15922564 15805193

Sources:
DrugBank ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

blocker (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

PMIDs:
15805193

Sources:
DrugBank ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
9182861

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
15458527

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
FDA